Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Pharyngitis01:23

Chronic Pharyngitis

12.2K
Chronic pharyngitis refers to persistent inflammation of the pharyngial mucosa.
Etiology
It often arises from persistent viral or bacterial infections affecting sinuses and tonsils.
Additional contributing factors include inadequate dental hygiene, mouth breathing, recurring tonsillitis, allergic rhinitis, laryngopharyngeal reflux, and exposure to smoke, chemicals, and other environmental pollutants. Allergic reactions to pollen, mold, and pet dander, chronic cough, excessive voice usage,...
12.2K
Chronic Pancreatitis I: Introduction01:24

Chronic Pancreatitis I: Introduction

745
The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
745
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

808
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
808
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

375
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
375
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

742
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
742
Chronic Obstructive Pulmonary Disease01:24

Chronic Obstructive Pulmonary Disease

2.6K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
2.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ALADA Dose Optimization in the Computed Tomography of the Temporal Bone: The Diagnostic Potential of Different Low-Dose CT Protocols.

Diagnostics (Basel, Switzerland)·2021
Same author

Clonal dynamics in a composite chronic lymphocytic leukemia and hairy cell leukemia-variant.

Genes, chromosomes & cancer·2020
Same author

What comes after the lockdown? Clustering of ANCA-associated vasculitis: single-centre observation of a spatiotemporal pattern.

Annals of the rheumatic diseases·2020
Same author

The prognostic value of additional copies of 1q21 in multiple myeloma depends on the primary genetic event.

American journal of hematology·2020
Same author

Magnetic resonance cholangiopancreatography with compressed sensing at 1.5 T: clinical application for the evaluation of branch duct IPMN of the pancreas.

European radiology·2020
Same author

Five-year survival follow-up of a phase III randomised trial comparing ofatumumab versus physicians' choice for bulky fludarabine-refractory chronic lymphocytic leukaemia: a short report.

British journal of haematology·2020

Related Experiment Video

Updated: Feb 8, 2026

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

22.5K

Chronic lymphocytic leukemia at ASH 2017.

David Wanner1, Michael Steurer1

  • 1Medical University Innsbruck, Innsbruck, Austria.

Memo
|July 10, 2018
PubMed
Summary

Two novel combinations show promising efficacy and safety for chronic lymphocytic leukemia treatment. Venetoclax with rituximab or ibrutinib may become new standards for relapsed/refractory and high-risk first-line disease.

Area of Science:

  • Hematology
  • Oncology
  • Clinical Trials

Background:

  • Chronic lymphocytic leukemia (CLL) remains a significant hematologic malignancy.
  • Effective treatment options for relapsed/refractory and high-risk first-line CLL are crucial.
  • Advances in targeted therapies are transforming CLL management.

Purpose of the Study:

  • To evaluate the efficacy and safety of novel combination therapies in chronic lymphocytic leukemia.
  • To assess the potential of venetoclax-based regimens in different patient settings.
  • To identify new standard-of-care treatment options for CLL.

Main Methods:

  • Presentation of clinical trial data from the American Society of Hematology (ASH) 2017 meeting.
  • Analysis of combination therapies including venetoclax with rituximab and ibrutinib with venetoclax.
Keywords:
ASHChronic lymphocytic leukemiaIbrutinibVenetoclax

More Related Videos

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

14.2K
HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

11.6K

Related Experiment Videos

Last Updated: Feb 8, 2026

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

22.5K
From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

14.2K
HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

11.6K
  • Evaluation of outcomes in relapsed/refractory and first-line high-risk CLL patients.

    • Main Results:

    • Striking efficacy observed with venetoclax plus rituximab combination therapy.
    • Significant clinical benefit demonstrated by ibrutinib plus venetoclax combination.
    • Manageable safety profiles reported for both investigated treatment regimens.
    • Promising results presented for both relapsed/refractory and first-line high-risk CLL settings.

    Conclusions:

    • Venetoclax combinations with rituximab or ibrutinib show high efficacy and acceptable safety.
    • These novel combinations represent potential new standard treatment options for chronic lymphocytic leukemia.
    • Further research and clinical adoption are warranted for these promising CLL therapies.